Administration of an investigational drug in the 28 days before the first dose of study treatment
Patients must not have received an investigational drug within 14 days
Participants may not be receiving treatment with any investigational drug or biologic within 30 days of randomization or at any time during the study.
Use of an investigational small molecule drug during the 30 days prior to screening or use of an investigational oligonucleotide or biologic drug during the prior 90 days
Patients who have received treatment with an investigational drug within 30 days preceding the first dose of study medication
The patient has received an investigational drug within 30 days of the first dose of study drug.
Treatment with any investigational drug 30 days prior to randomization
Patient has received an investigational drug within 14 days of enrollment
Any other investigational drug within 30 days prior to registration and during the study
Has received an investigational therapy within 30 days of first dose of study drug
Treatment with an investigational drug study within 28 days of before starting on study treatment
Treatment with any investigational drug within 30 days prior to registration.
Investigational drug use within 28 days of C1D1
Any investigational drug within 28 days prior to study treatment.
Use of any investigational drug within 14 days prior to the first dose of study drug
Patients who have been treated with an investigational agent within 21 days prior to the first dose of study drug.
The use of another investigational drug within the previous 30 days
Investigational therapy, defined as any drug that has not been approved for marketing for any indication in cGVHD will be restricted from the study
Treatment with a non-approved or investigational drug within 30 days prior to day 1 of study treatment
Patients who have received treatment with an investigational drug within 30 days preceding the first dose of study medication
Use of other investigational drug within 28 days of enrollment.
Treatment with a non-approved or investigational drug within 28 days of study treatment
Recipient must not have received any investigational drug within 30 days of starting conditioning treatment
Received an investigational drug within 30 days of starting treatment, or have not recovered from side effects of an investigational drug
Patients receiving an investigational drug within 10 days prior to registration
Received any investigational compound within 28 days prior to the first dose of study drug or planned during the treatment period or follow-up
Participation in any investigational drug study within 28 days prior to initiation of treatment within this protocol; (subject must have recovered from all acute effects of previously administered investigational agents)
Treatment with a non-approved or investigational drug within 28 days of study treatment
Investigational agent received within 30 days prior to the first dose of study drug; if received any investigational agent prior to this time point, drug-related toxicities must have recovered to grade 2 or less prior to first dose of study drug
Concurrent enrollment in any other study using an investigational drug
Patient may not be receiving any other investigational drug
Participation in an investigational drug study or history of receiving any investigational treatment within 30 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer.
Treatment with an approved or investigational chemotherapy drug within 28 days of Day 1
Treatment with an approved or investigational anti-CD20 drug within 28 days of Day 1
Treatment with an approved or investigational biologic drug that does not target CD20 within 90 days of Day 1
Patient on other investigational drug
Treatment with an investigational therapeutic drug within 30 days of cycle 1
Patients participating in an investigational new drug protocol within 14 days before enrollment.
Prior therapy with TEW-7197 or received any investigational drug within the prior 28 days
Treatment with any investigational drug within 30 days prior to registration.
Use of any other investigational drug
Any anti-cancer treatment within 14 days or any investigational agent within 30 days before the first dose of study drug.
Use of any investigational drug within 14 days prior to the first dose of study drug
Treatment with any investigational drug within 28 days before randomisation.
Investigational drug within 30 days of first trilaciclib (G1T28) dose
Administration of any investigational agent within 28 days of first dose of study drug
Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study
Treatment with any investigational drug within 28 days prior to randomization
Another investigational drug
Patients participating in an investigational new drug protocol within 14 days before enrollment
Treatment with a non-approved or investigational drug within 30 days before day 1 of study treatment
Administration of any investigational agent within 28 days of first dose of study drug
Investigational drug use within 28 days of randomization.
Subjects who have received investigational agents within 28 days of the first day of study drug.
Patient who has participated in a prior therapeutic investigational drug study within 30 days prior to enrollment
Patients must not have prior treatment with any investigational drug within the preceding 28 days and must not be planning to receive any other investigational drug for the duration of the study
Participation in any investigational drug study within 28 days prior to initiation of treatment within this protocol; (subject must have recovered from all acute effects of previously administered investigational agents)
Use of any investigational drug (including marketed drugs not approved for this indication) within 14 days prior to the first dose of study drug
Other investigational treatment during or within 21 days before starting study treatment
Use of an investigational treatment from 30 days prior to the first dose of SNX-5422 and during the study.
History of receiving any investigational treatment within 21 days prior to enrollment into the study
Administration of any non-oncologic investigational drug within 28 days prior to receiving the first dose of therapy
Use of an investigational anti-cancer drug within 28 days preceding the first dose of dabrafenib
Treatment with any anti-cancer investigational drug within 28 days prior to commencing study treatment
Treatment with a non-approved or investigational drug within 30 days before visit 1
Receipt of another investigational drug within 14 days of enrollment.
Patients receiving other investigational medication (including investigational immunotherapy for NSCLC) or having received such medication within 30 days before entering the protocol
Patients may not be receiving any other investigational agents nor have received any investigational drug 30 days prior to enrollment
Use of an investigational drug within 30 days prior to screening.
Investigational agent received within 30 days prior to the first dose of study drug; if received any investigational agent prior to this time point, drug-related toxicities must have recovered to grade 2 or less prior to first dose of study drug
Chemotherapy or investigational drug therapy for cancer up to 21 days prior to day-1 of study.
Participation in any investigational drug study within 28 days prior to ISF35 administration; (subject must have recovered from all acute effects of previously administered investigational agents)
Treatment with a non-approved or investigational drug or agent within 30 days before day 1 of trial treatment
Treatment with an unapproved, investigational agent within 21 days of the first dose of study drug
Treatment with any investigational anticancer drug within 21 days of the first study\n             treatment administration
investigational drug within 28 days
investigational drug within the 28 days prior to planned first dose of study drug, or
Patients who have received any investigational drug within 28 days prior to Day 1 of study entry (an investigational drug is one for which there is no approved indication), or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy
Treatment with a non-approved or investigational drug within 30 days prior to day 1 of study treatment
Treatment with an unapproved, investigational therapeutic agent, immunotherapy or biological therapy within 21 days prior to the first dose of study drug
Receipt of an investigational drug within 28 days prior to initiation of study treatment
Receipt of an investigational drug within 28 days prior to study start
Investigational drug use within 28 days of the first dose of PLX3397
Treatment with a investigational drug within 28 days before Day 1 of trial treatment.
Treatment within the last 30 days with any investigational drug
Use of an investigational therapeutic within 30 days
Patients who have received any investigational medication within 6 weeks of enrollment, or who are scheduled to receive an investigational drug during the course of the study
Subjects who are receiving any other investigational agents or have received another investigational drug in the last 30 days
Enrollment in another investigational drug trial
Patients who have received any investigational medication within 6 weeks of enrollment, or who are scheduled to receive an investigational drug during the course of the study
Patient receiving any investigational drug for hyperuricemia within 30 days of planned first treatment with rasburicase
Any investigational drug being administered during the study
Treatment with any investigational drug or investigational biologic within 30 days of initiating study treatment or during the study
Treatment with any investigational drug or investigational biologic within 30 days of initiating study treatment or during the study
Patient aged < 6 years who received any investigational drug (defined as a medication with no marketing authorization granted for any age class and any indication) within 90 days prior to Day 1, or patient aged 6 years who received any investigational drug within 30 days prior to Day 1 or is expected to receive investigational drugs prior to study completion.
Patients who have received an investigational drug within 30 days of enrollment in study
Has participated in any Phase 1 Investigational New Drug (IND) study within prior 30 days or expects to do so within the following 60 days
Have received any investigational new drug within the past 30 days or planning to receive such during the study period
Administration of chemotherapy or any investigational drug in the 28 days prior to receiving the first dose of treatment.
Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours (h) afterwards
Treatment with another investigational drug or other intervention with 24 hours of injection
Received an investigational drug within 30 days prior to first dose of panitumumab IRDye800
Received an investigational drug within 30 days prior to first dose of cetuximab IRDye800
Patient must not be receiving an investigational drug
Received an investigational drug within 30 days prior to first dose of cetuximab-IRDye800
Treatment with other investigational study drug for any indication for any reason, or receipt of anticancer medications within 28 days before first dose of study drug; subjects must have recovered from AEs due to previously administered therapies.
Received investigational therapy with another drug or biologic within 30 days prior to the start of CMP-001 dosing on W1D1. However, if an investigational drug has a short half-life, a shorter wash out period may be acceptable upon permission given by the Sponsor.
Investigational drug use within 28 days of the first dose of avelumab
Received an investigational drug within 30 days prior to first dose of cetuximab IRDye800
Administration of any investigational therapeutic within 30 days of enrollment
Have taken an investigational drug within 30 days of enrollment.
The patient has received an investigational drug within 30 days of the first dose of study drug.
Subjects who have taken an investigational drug within 30 days of enrollment.
Subjects who have taken an investigational drug within 30 days of enrollment.
Use of an investigational drug within 21 days prior to the first dose of study drug. Note that to be eligible, any drug-related toxicity should have recovered to Grade 1 or less, with the exception of alopecia.
